About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 143273, 9 pages
http://dx.doi.org/10.1155/2013/143273
Clinical Study

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

1Medical Oncology, S. Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy
2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L'Aquila, Italy
3Radiology, S. Salvatore Hospital, 67100 L'Aquila, Italy
4Hepatobiliar-Pancreatic Surgery, S. Salvatore Hospital, 67100 L'Aquila, Italy

Received 26 June 2013; Revised 31 August 2013; Accepted 13 September 2013

Academic Editor: Hidekazu Kuramochi

Copyright © 2013 Gemma Bruera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Among Supplementary material, Table 1 describes KRAS mutations detected; Table 2 describes received dose-intensities; Table 3 describes toxicities characterizing limiting toxicity syndromes in individual patients; Table 4 describes activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype and extension of metastatic disease; Figure 1 reports progression-free survival and overall survival of KRAS wild-type patients (A) and KRAS mutant patients (B), liver-limited versus other/multiple metastatic disease.

  1. Supplementary Material